Oric Pharmaceuticals, Inc. Common StockORIC

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain penetrant inhibitor that selectively targets EGFR exon 20 and atypical mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego.

oricpharma.com